phrykt

Kiniksa Pharmaceuticals International, plc (KNSA): who owns it and who trades it

As of Nov 16, 2026, KNSA insiders reported 89 open-market sales worth $122M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sanj K Patel (CEO), with $81.1M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Kiniksa Pharmaceuticals International

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KNSA

266 funds and institutions reported KNSA shares worth $3B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $446M.

10 largest owners, by value

FMR LLC (Fidelity)$446M
Rubric Capital Management LP$256M
Baker Bros. Advisors LP$181M
BlackRock, Inc.$175M
Tang Capital Management LLC$145M
Vanguard Portfolio Management LLC$122M
Vanguard Capital Management LLC$87M
Morgan Stanley$64.7M
Arrowstreet Capital, Limited Partnership$61.2M
Spruce Street Capital LP$58.7M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)6.97M–$446M+2%
Rubric Capital Management LP4.00M–$256M+7%
Baker Bros. Advisors LP2.83M–$181M+0%
BlackRock, Inc.2.74M–$175M+463%
Tang Capital Management LLC2.26M–$145MNo change
Vanguard Portfolio Management LLC1.91M–$122M+8%
Vanguard Capital Management LLC1.36M–$87M+2%
Morgan Stanley1.01M–$64.7M+1%
Arrowstreet Capital, Limited Partnership957,514–$61.2M+7%
Spruce Street Capital LP918,070–$58.7M+21%
Dimensional Fund Advisors LP874,786–$55.9M+8%
Invesco Ltd.772,806–$49.4M+2694%
Driehaus Capital Management LLC718,199–$45.9M+17%
State Street Corp704,194–$45M+819%
Acadian Asset Management LLC679,083–$43.4M-49%
Point72 Asset Management, L.P.659,493–$42.2M+3%
Rice Hall James & Associates, LLC624,928–$40M+3%
Pictet Asset Management Holding SA608,650–$38.9M-2%
Geode Capital Management, LLC604,180–$38.6M+1263%
Jupiter Topco LLC586,177–$37.5M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KNSA insiders reported $0 of open-market purchases and $122M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$122M
89 trades, 8 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 12, 2026

Purchases and sales by month

$51.9M$51.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan11,280$98.54$1.1MForm 4
Nov 4, 2026Sanj K PatelCEOSale plan1,460$92.35$135KForm 4
Nov 4, 2026Sanj K PatelCEOSale plan11,335$93.54$1.1MForm 4
Nov 4, 2026Sanj K PatelCEOSale plan81,742$94.20$7.7MForm 4
Nov 4, 2026Sanj K PatelCEOSale plan29,845$95.48$2.8MForm 4
Nov 4, 2026Sanj K PatelCEOSale plan26,918$96.05$2.6MForm 4
Nov 3, 2026Sanj K PatelCEOSale plan1,214$90.77$110KForm 4
Nov 3, 2026Sanj K PatelCEOSale plan68,664$92.70$6.4MForm 4
Nov 3, 2026Sanj K PatelCEOSale plan145,708$93.53$13.6MForm 4
Nov 3, 2026Sanj K PatelCEOSale plan4,584$94.25$432KForm 4
Nov 2, 2026Sanj K PatelCEOSale plan38,364$91.03$3.5MForm 4
Nov 2, 2026Sanj K PatelCEOSale plan24,188$91.83$2.2MForm 4
Nov 2, 2026Sanj K PatelCEOSale plan26,781$93.06$2.5MForm 4
Nov 2, 2026Sanj K PatelCEOSale plan100$93.97$9.4KForm 4
Nov 2, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan899$92.37$83KForm 4
Nov 2, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan16,810$93.42$1.6MForm 4
Nov 2, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan704$94.09$66.2KForm 4
Nov 2, 2026Mark RagosaCFOSale plan14,027$91.40$1.3MForm 4
Nov 2, 2026Mark RagosaCFOSale plan10,502$92.03$966KForm 4
Nov 2, 2026Mark RagosaCFOSale plan12,034$93.13$1.1MForm 4
Nov 2, 2026Mark RagosaCFOSale plan220$94.01$20.7KForm 4
Nov 2, 2026Ross MoatCHIEF OPERATING OFFICERSale plan6,681$91.23$610KForm 4
Nov 2, 2026Ross MoatCHIEF OPERATING OFFICERSale plan8,932$92.05$822KForm 4
Nov 2, 2026Ross MoatCHIEF OPERATING OFFICERSale plan11,642$93.15$1.1MForm 4
Nov 2, 2026Ross MoatCHIEF OPERATING OFFICERSale plan722$94.05$67.9KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan6,030$91.87$554KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan6,831$92.77$634KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan9,508$94.20$896KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan3,705$94.86$351KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan3,145$96.08$302KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan1,691$97.11$164KForm 4
Oct 30, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan5,350$97.74$523KForm 4
Oct 30, 2026Sanj K PatelCEOSale plan41,169$92.01$3.8MForm 4
Oct 30, 2026Sanj K PatelCEOSale plan18,685$92.77$1.7MForm 4
Oct 30, 2026Sanj K PatelCEOSale plan15,903$93.62$1.5MForm 4
Oct 30, 2026Sanj K PatelCEOSale plan8,888$94.72$842KForm 4
Oct 30, 2026Sanj K PatelCEOSale plan4,490$95.97$431KForm 4
Oct 30, 2026Sanj K PatelCEOSale plan2,316$97.34$225KForm 4
Oct 30, 2026Sanj K PatelCEOSale plan1,440$98.16$141KForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan41,789$92.02$3.8MForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan16,056$92.85$1.5MForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan6,841$93.91$642KForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan4,821$94.86$457KForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan4,000$95.97$384KForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan1,925$97.06$187KForm 4
Oct 30, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan2,155$97.77$211KForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan37,775$92.00$3.5MForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan15,114$92.81$1.4MForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan8,430$93.97$792KForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan6,282$94.92$596KForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan3,672$96.03$353KForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan1,760$97.10$171KForm 4
Oct 30, 2026Ross MoatCHIEF OPERATING OFFICERSale plan2,575$97.76$252KForm 4
Sep 3, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan4,600$80.30$369KForm 4
Jul 29, 2026G Bradley ColeDirectorSale3,673$81.43$299KForm 4
May 1, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan37,327$53.52$2MForm 4
May 1, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan21,097$54.04$1.1MForm 4
May 1, 2026Sanj K PatelCEOSale plan48,565$54.02$2.6MForm 4
Apr 30, 2026Sanj K PatelCEOSale plan2,141$54.01$116KForm 4
Apr 29, 2026Sanj K PatelCEOSale plan22,544$54.01$1.2MForm 4
Apr 28, 2026Sanj K PatelCEOSale plan51,750$54.02$2.8MForm 4
Apr 28, 2026Sanj K PatelCEOSale plan243,596$52.02$12.7MForm 4
Apr 28, 2026Sanj K PatelCEOSale plan113,673$51.47$5.9MForm 4
Apr 28, 2026Sanj K PatelCEOSale plan74,635$50.43$3.8MForm 4
Apr 28, 2026Barry D QuartDirectorSale plan13,099$50.10$656KForm 4
Apr 9, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale plan6,625$46.69$309KForm 4
Apr 9, 2026Ross MoatCHIEF OPERATING OFFICERSale plan1,703$46.69$79.5KForm 4
Apr 6, 2026Sanj K PatelCEOSale plan7,278$50.01$364KForm 4
Apr 6, 2026Ross MoatCHIEF OPERATING OFFICERSale plan2,367$48.58$115KForm 4
Apr 6, 2026Barry D QuartDirectorSale plan6,901$50.00$345KForm 4
Mar 9, 2026Mark RagosaCFOSale plan18,741$46.24$867KForm 4
Mar 9, 2026Mark RagosaCFOSale plan17,981$45.58$820KForm 4
Mar 2, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan5,714$45.92$262KForm 4
Mar 2, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan22,223$44.88$997KForm 4
Mar 2, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale plan12,063$44.20$533KForm 4
Feb 12, 2026Barry D QuartDirectorSale plan2,690$45.00$121KForm 4
Feb 10, 2026Barry D QuartDirectorSale plan110$45.00$5KForm 4
Feb 9, 2026Mark RagosaCFOSale plan9,114$42.85$391KForm 4
Feb 9, 2026Mark RagosaCFOSale plan8,731$43.72$382KForm 4
Feb 4, 2026Barry D QuartDirectorSale plan2,602$45.02$117KForm 4
Feb 3, 2026Barry D QuartDirectorSale plan12,528$45.27$567KForm 4
Feb 2, 2026Barry D QuartDirectorSale plan830$45.00$37.4KForm 4
Jan 8, 2026Mark RagosaCFOSale plan12,000$41.89$503KForm 4
Dec 15, 2025Barry D QuartDirectorSale plan20,129$41.51$836KForm 4
Dec 15, 2025Eben TessariCHIEF OPERATING OFFICERSale plan12,048$41.56$501KForm 4
Dec 8, 2025Mark RagosaCFOSale plan42,841$41.49$1.8MForm 4
Nov 26, 2025Eben TessariCHIEF OPERATING OFFICERSale plan200$42.89$8.6KForm 4
Nov 17, 2025Eben TessariCHIEF OPERATING OFFICERSale plan645$40.08$25.9KForm 4
Nov 17, 2025Eben TessariCHIEF OPERATING OFFICERSale plan11,825$41.30$488KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Sanj K PatelCHAIRMAN & CEO, Director–$81.1MNov 4, 2026
John F. PaoliniCHIEF MEDICAL OFFICER–$13.9MNov 2, 2026
Ross MoatCHIEF OPERATING OFFICER–$9.8MNov 2, 2026
Mark RagosaCHIEF FINANCIAL OFFICER–$8.1MNov 2, 2026
Michael R MegnaCHIEF ACCOUNTING OFFICER–$5.2MNov 9, 2026
Barry D QuartDirector–$2.7MApr 28, 2026
Eben TessariCHIEF OPERATING OFFICER–$1MDec 15, 2025
G Bradley ColeDirector–$299KJul 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KNSA short interest

4.29M KNSA shares are sold short. Over the last 12 reports the number of shares short went up 35%.

As of Oct 30, 2026, 4.29M KNSA shares were sold short, up 14.1% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short

4.29MMay 15Oct 304.74M

Days to cover

3.9May 15Oct 3010.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.29M–+14%1.10M3.9
Oct 15, 20263.76M–-0%555,4806.8
Sep 30, 20263.78M–-3%589,0576.4
Sep 15, 20263.88M–+2%537,8557.2
Aug 31, 20263.79M–-12%436,0508.7
Aug 14, 20264.28M–-1%447,9529.6
Jul 31, 20264.32M–-4%865,0125.0
Jul 15, 20264.51M–+9%658,5026.8
Jun 30, 20264.15M–+41%1.44M2.9
Jun 15, 20262.95M–-3%514,6155.7
May 29, 20263.04M–-4%547,3775.6
May 15, 20263.18M–-10%572,4845.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Kiniksa Pharmaceuticals International company events

Kiniksa Pharmaceuticals International filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 27, 2026.

  1. Oct 27, 2026ResultsReleased financial results. Filing
  2. Oct 22, 2026LeadershipThe Compensation Committee of the Board of Directors of Kiniksa Pharmaceuticals International, plc appointed Ross Moat as President and Chief Operating Officer, effective immediately. Filing
  3. Jul 28, 2026ResultsReleased financial results. Filing
  4. May 29, 2026VoteReported shareholder vote results. Filing
  5. May 26, 2026AgreementKiniksa Pharmaceuticals International, plc entered into a deed of waiver with Baker Bros. Filing
  6. May 1, 2026LeadershipEben Tessari informed Kiniksa Pharmaceuticals International, plc of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry. Filing
  7. Apr 28, 2026ResultsReleased financial results. Filing
  8. Feb 24, 2026ResultsReleased financial results. Filing
  9. Jan 14, 2026LeadershipThe Board of Directors of Kiniksa Pharmaceuticals International, plc appointed Ross Moat to the position of Chief Operating Officer and principal operating officer. Filing
  10. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Kiniksa Pharmaceuticals International financials

Famous investors that hold KNSA

5 of the 50 well-known investors we track reported holding KNSA in their latest 13F filing. The largest position is Steve Cohen's, worth $40.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026548,496$40.9M0.1%-17%
Ken Griffin · Citadel AdvisorsQ3 2026421,176$31.4M0.0%+911%
Ken Fisher · Fisher Asset ManagementQ3 2026323,808$24.2M0.0%-19%
Jim Simons · Renaissance TechnologiesQ3 2026165,477$12.3M0.0%+143%
Israel Englander · Millennium ManagementQ3 202695,826$7.1M0.0%+3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KNSA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Rubric Capital Management LP13G/A5.8%
Nov 16, 2026Rubric Capital Management LP13G/A5.8%

Questions about Kiniksa Pharmaceuticals International, plc (KNSA) stock

Who owns the most KNSA stock?

The largest reported owner of Kiniksa Pharmaceuticals International, plc (KNSA) is FMR LLC (Fidelity). In total, 266 funds and institutions reported holding KNSA at the end of Q2 2026. See the largest owners.

Are KNSA insiders buying or selling?

In the last 12 months, KNSA insiders reported no open-market purchases and 89 sales worth $122M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in KNSA?

As of Oct 30, 2026, 4.29M KNSA shares were sold short, up 14.1% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold KNSA?

5 of the 50 well-known investors we track reported KNSA in their latest 13F filing, including Steve Cohen, Ken Griffin, Ken Fisher. The largest position is worth $40.9M. See all holders.

Executive pay

Kiniksa Pharmaceuticals International's chief executive was paid a total of $10.8M for the year ended Dec 31, 2025, up 54% from $7M the year before. In the last 12 months, Kiniksa Pharmaceuticals International's executives and directors bought no stock on the open market and sold $122M.

Chief executive, total pay$10.8MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$28.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.